

Comment on: “Clinical interrogation of *TP53* aberrations and its impact on survival in patients with myeloid neoplasms”

The study by Senapati *et al.* provides a comprehensive retrospective analysis of the impact of *TP53* aberrations on outcomes in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), highlighting the prognostic significance of *TP53* mutational burden, disease subtype, and the role of allogeneic hematopoietic stem cell transplantation (HSCT).¹ While the authors present valuable insights into the clinical relevance of *TP53* allelic status and treatment outcomes, several aspects warrant further discussion, including the implications of *TP53* heterogeneity, the limitations of retrospective design, and the need for prospective validation of risk stratification models.

The classification of *TP53* aberrations into high-risk (TP53HR) and low-risk (TP53LR) groups based on variant allele frequency (VAF), allelic loss, or multiple mutations is a pragmatic approach. However, the biological heterogeneity of *TP53* mutations - such as missense *versus* truncating mutations - may further influence outcomes. For instance, missense mutations often exhibit dominant-negative effects or gain-of-function properties, which could exacerbate disease aggressiveness.² The study briefly mentions the prevalence of missense mutations (87%) but does not explore their differential impact on survival. Future analyses could stratify outcomes by mutation type to refine prognostic models.

The study’s retrospective nature and the predominance of patients treated at a single tertiary center may introduce selection bias. Patients enrolled in clinical trials (75% of the cohort) often have better performance status and access to novel therapies, potentially skewing survival estimates. Additionally, the exclusion of patients with missing cytogenetic data or low blast counts (<5%) may underrepresent the true diversity of *TP53*-mutated myeloid neoplasms. Prospective, multicenter studies are needed to validate these findings in broader populations.³

The study reaffirms HSCT as a critical intervention for *TP53*-mutated MDS/AML, with transplanted patients achieving superior survival (median overall survival [OS]: 14 months in AML, 17.3 months in MDS). However, the benefit was most pronounced in patients achieving measurable residual disease (MRD)-negative remission pre-HSCT (median OS 29.5 months). This underscores the importance of MRD assessment, yet the study does not detail MRD monitoring methods or its consistency across patients. Standardized MRD protocols, such as next-generation sequencing or multiparameter flow cytometry, could enhance predictive accuracy.⁴

While venetoclax-based regimens improved response rates (overall response 66% vs. 48%), they did not translate into survival benefits, contrasting with prior reports.⁵ This discrepancy may reflect the high prevalence of TP53HR (87%) in the cohort, a subgroup known for venetoclax resistance.⁶ The lack of survival advantage also questions whether venetoclax merely selects for less aggressive clones without altering disease biology. Conversely, the equivalence of intensive and low-intensity therapy in younger patients (<60 years) challenges the dogma that *TP53*-mutated AML universally benefits from reduced-intensity approaches.⁷ The study notes superior survival in MDS (median OS 10.8 months) *versus* AML (median OS 5.9 months), even within TP53HR subgroups. This aligns with recent debates about the arbitrary 20% blast cutoff for AML/MDS classification.⁸ However, the absence of survival differences between MDS patients with 5-10% *versus* >10% blasts suggests that *TP53* aberrations may override traditional blast-based prognostication. This supports calls for integrating molecular profiling into diagnostic criteria.⁹

The study’s validation of a 40% VAF cutoff for TP53HR (corroborated by machine learning) is clinically actionable, but dynamic monitoring of *TP53* clones during therapy could refine risk assessment. Emerging therapies targeting p53 stabilization (e.g., eprenetapopt) or immune-based strategies may benefit TP53HR patients, particularly in combination with HSCT.¹⁰

In conclusion, Senapati *et al.* provide a robust framework for *TP53* risk stratification, but prospective studies addressing mutation heterogeneity, MRD, and novel therapies are needed to optimize outcomes in this high-risk population.

Authors

Hamza Sajid

Allama Iqbal Medical College, Lahore, Pakistan

Correspondence:

H. SAJID - hamzasajid490@gmail.com

<https://doi.org/10.3324/haematol.2025.288479>

Received: June 16, 2025.

Accepted: October 1, 2025.

Early view: October 9, 2025.

Disclosures

No conflicts of interest to disclose.

References

1. Senapati J, Loghavi S, Garcia-Manero G, et al. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. *Haematologica*. 2025;110(6):1304-1315.
2. Prokocimer M, Molchadsky A, Rotter V. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. *Blood*. 2017;130(6):699-712.
3. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. *Blood*. 2022;140(12):1345-1377.
4. Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. *Blood*. 2021;138(26):2753-2767.
5. Pollyea DA, Pratz KW, Wei AH, et al. Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine. *Clin Cancer Res*. 2022;28(24):5272-5279.
6. Nechiporuk T, Kurtz SE, Nikolova O, et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. *Cancer Discov*. 2019;9(7):910-925.
7. DiNardo CD, Garcia-Manero G, Kantarjian HM, et al. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). *Am J Hematol*. 2016;91(2):227-232.
8. Estey E, Hasserjian RP, Döhner H, et al. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. *Blood*. 2022;139(3):323-332.
9. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. *Blood*. 2022;140(11):1200-1228.
10. Garcia-Manero G, Goldberg AD, Winer ES, et al. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukemia: a phase 1, dose-finding and expansion study. *Lancet Haematol*. 2023;10(4):e272-e283.